REPL Overview

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Replimune Group Inc revenue for the last quarter amounts to -71.87M USD, increased 8.86

Replimune Group Inc. EPS for the last quarter amounts to -66090000.00 USD, increased 25.85

Replimune Group Inc (REPL) has 479 emplpoyees as of March 11 2026.

Today REPL has the market capitalization of 679.57M USD.